SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Catovsky D,Ikoku NB,Pitney WR,Galton DA. Thromboembolic complications in myelomatosis. BMJ. 1970; 3: 438439.
  • 2
    Elice F,Fink L,Tricot G,Barlogie B,Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006; 134: 399405.
  • 3
    Zangari M,Saghafifar F,Mehta P,Barlogie B,Fink L,Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost. 2003; 29: 275282.
  • 4
    Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc. 2005; 80: 15491551.
  • 5
    Osman K,Comenzo R,Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001; 344: 1951192.
  • 6
    Rajkumar SV,Blood E,Vesole D,Fonseca R,Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24: 431436.
  • 7
    Cavo M,Zamagni E,Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood. 2002; 100: 2272223.
  • 8
    Anagnostopoulos A,Weber D,Rankin K,Delasalle K,Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003; 121: 768771.
  • 9
    Richardson PG,Schlossman RL,Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100: 30633067.
  • 10
    Rajkumar SV,Hayman SR,Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005; 106: 40504053.
  • 11
    Richardson PG,Mitsiades C,Hideshima T,Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006; 6: 11651173.
  • 12
    Zonder JA. Thrombotic complications of myeloma therapy. Hematology. 2006: 348355.
  • 13
    Knight R,DeLap RJ,Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006; 354: 20792080.
  • 14
    Durie BGM,Richardson P,Palumbo A, et al. Deep vein thrombosis in myeloma: estimate of prevelance and recommendations for therapy based upon a survey of members of the International Myeloma Working Group (IMWG) [abstract]. ASH Annu Meet Abstr. 2006; 108: 3571.
  • 15
    Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest. 2007; 131: 275277.
  • 16
    Bennett CL,Angelotta C,Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006; 296: 25582560.
  • 17
    Rajkumar SV,Jacobus S,Callander N,Fonseca R,Vesole D,Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. ASH Annu Meet Abstr. 2006; 108: 799.
  • 18
    Dimopoulos MA,Spencer A,Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. ASH Annu Meet Abstr. 2005; 106: 6.
  • 19
    Cohen AT,Skinner JA,Kakkar VV. Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? BMJ. 1994; 309: 12131215.
  • 20
    [No authors listed.] Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355: 12951302.
  • 21
    Cohen A,Quinlan D. PEP trial. Lancet. 2000; 356: 247.
  • 22
    Hovens MMC,Snoep JD,Tamsma JT,Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemostasis. 2006; 4: 14701475.
  • 23
    Geerts WH,Pineo GF,Heit JA, et al. Prevention of venous thromboembolism: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126( suppl 3): 338S400S.
  • 24
    Baz R,Li L,Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005; 80: 15681574.
  • 25
    Zonder JA,Durie BGM,McCoy J, et al. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis [abstract]. ASH Annu Meet Abstr. 2005; 106: 3455.
  • 26
    Rajkumar SV,Jacobus S,Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol (Meet Abstr). 2007; 25( 18 suppl): LBA8025.
  • 27
    Weber D,Wang M,Chen C, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function [abstract]. ASH Annu Meet Abstr. 2006; 108: 3547.
  • 28
    Richardson PG,Blood E,Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006; 108: 34583464.